Work

Advantage of adding 131I MIBG to 90Y DOTATOC for treatment of patients with advanced stage neuroendocrine tumors

Year: 2014

Type: article

Source: Journal of Nuclear Medicine

Authors: David Bushnell, Mark T. Madsen, Thomas M. O’Dorisio, Yusuf Menda, Saima Muzahir, Randi J. Ryan, Ian M. Besse, M. Sue O’Dorisio

Institutions: Iowa City VA Medical Center, University of Iowa, University of Iowa Hospitals and Clinics, University of Wisconsin–Madison, Pacific University

Language: English

Topic: Neuroendocrine Tumor Research Advances

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2231642646

FWCI:

Cites:

Cited by:

Related to: 10